Terms: = Prostate cancer AND ATR, Q13535, 545, ENSG00000175054, MEC1, SCKL, SCKL1, FRP1 AND Prognosis
25 results:
1. Prognostic Significance of Radiographic Lymph Node Invasion in Contemporary Metastatic Renal Cell Carcinoma Patients.
Scheipner L; Incesu RB; Morra S; Baudo A; Assad A; Jannello LMI; Siech C; de Angelis M; Tian Z; Saad F; Shariat SF; Briganti A; Chun FKH; Tilki D; Longo N; Carmignani L; De Cobelli O; Pichler M; Ahyai S; Karakiewicz PI
Clin Genitourin Cancer; 2024 Apr; 22(2):164-170. PubMed ID: 37981546
[TBL] [Abstract] [Full Text] [Related]
2. Analysis of risk factors for positive surgical margin after laparoscopic radical prostatectomy with and without neoadjuvant hormonal therapy.
Wang F; Zhang G; Tang Y; Wang Y; Li J; Xing N
Front Endocrinol (Lausanne); 2023; 14():1270594. PubMed ID: 37941905
[TBL] [Abstract] [Full Text] [Related]
3. LncRNA weighted gene co-expression network analysis reveals novel biomarkers related to prostate cancer metastasis.
Liu M; Chen MY; Huang JM; Liu Q; Wang L; Liu R; Yang N; Huang WH; Zhang W
BMC Med Genomics; 2022 Dec; 15(1):256. PubMed ID: 36514044
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic Role of DNA Damage Response Genes Mutations and their Association With the Sensitivity of Olaparib in prostate cancer Patients.
Zhang D; Xu X; Wei Y; Chen X; Li G; Lu Z; Zhang X; Ren X; Wang S; Qin C
Cancer Control; 2022; 29():10732748221129451. PubMed ID: 36283420
[TBL] [Abstract] [Full Text] [Related]
5. Characteristics and outcomes of heart transplant recipients with a pretransplant history of malignancy.
Youn JC; Kim D; Kim KA; Kim JJ; Kim IC; Lee HS; Choi JO; Jeon ES; Nishihara K; Kransdorf EP; Chang DH; Kittleson MM; Patel JK; Ramzy D; Esmailian F; Kobashigawa JA
Am J Transplant; 2022 Dec; 22(12):2942-2950. PubMed ID: 36050598
[TBL] [Abstract] [Full Text] [Related]
6. Ataxia-telangiectasia mutated and ataxia telangiectasia and Rad3-related kinases as therapeutic targets and stratification indicators for prostate cancer.
Gulliver C; Hoffmann R; Baillie GS
Int J Biochem Cell Biol; 2022 Jun; 147():106230. PubMed ID: 35609768
[TBL] [Abstract] [Full Text] [Related]
7. Loss of NEIL3 activates radiotherapy resistance in the progression of prostate cancer.
Wang Q; Li Z; Yang J; Peng S; Zhou Q; Yao K; Cai W; Xie Z; Qin F; Li H; Chen X; Li K; Huang H
Cancer Biol Med; 2021 Oct; 19(8):1193-210. PubMed ID: 34591415
[TBL] [Abstract] [Full Text] [Related]
8. Additive effects of variants of unknown significance in replication repair-associated DNA polymerase genes on mutational burden and prognosis across diverse cancers.
Ying J; Yang L; Yin JC; Xia G; Xing M; Chen X; Pang J; Wu Y; Bao H; Wu X; Shao Y; Zhu L; Cheng X
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479923
[TBL] [Abstract] [Full Text] [Related]
9. Deficiency of NEIL3 Enhances the Chemotherapy Resistance of prostate cancer.
Wang Y; Xu L; Shi S; Wu S; Meng R; Chen H; Jiang Z
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921035
[TBL] [Abstract] [Full Text] [Related]
10. Differences in Genomic Alterations Between Brain Metastases and Primary Tumors.
Dono A; Takayasu T; Yan Y; Bundrant BE; Arevalo O; Lopez-Garcia CA; Esquenazi Y; Ballester LY
Neurosurgery; 2021 Feb; 88(3):592-602. PubMed ID: 33369669
[TBL] [Abstract] [Full Text] [Related]
11. Age-related mutational signature negatively associated with immune activity and survival outcome in triple-negative breast cancer.
Chen H; Chong W; Yang X; Zhang Y; Sang S; Li X; Lu M
Oncoimmunology; 2020 Jun; 9(1):1788252. PubMed ID: 32923150
[TBL] [Abstract] [Full Text] [Related]
12. Antihypertensive drug use and prostate cancer-specific mortality in Finnish men.
Siltari A; Murtola TJ; Talala K; Taari K; Tammela TLJ; Auvinen A
PLoS One; 2020; 15(6):e0234269. PubMed ID: 32598349
[TBL] [Abstract] [Full Text] [Related]
13. Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion.
Fraune C; Harms L; Büscheck F; Höflmayer D; Tsourlakis MC; Clauditz TS; Simon R; Möller K; Luebke AM; Möller-Koop C; Steurer S; Hube-Magg C; Sauter G; Weidemann S; Lebok P; Dum D; Kind S; Minner S; Izbicki JR; Schlomm T; Huland H; Heinzer H; Burandt E; Haese A; Graefen M; Schroeder C
Mol Med; 2020 Mar; 26(1):24. PubMed ID: 32143573
[TBL] [Abstract] [Full Text] [Related]
14. Impact of GAS5 genetic polymorphism on prostate cancer susceptibility and clinicopathologic characteristics.
Lin CY; Wang SS; Yang CK; Li JR; Chen CS; Hung SC; Chiu KY; Cheng CL; Ou YC; Yang SF
Int J Med Sci; 2019; 16(11):1424-1429. PubMed ID: 31673232
[TBL] [Abstract] [Full Text] [Related]
15. Effect of DNA damage response mutations on prostate cancer prognosis: a systematic review.
Swift SL; Lang SH; White H; Misso K; Kleijnen J; Quek RG
Future Oncol; 2019 Oct; 15(28):3283-3303. PubMed ID: 31535940
[TBL] [Abstract] [Full Text] [Related]
16. atr inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D.
Komura K; Yoshikawa Y; Shimamura T; Chakraborty G; Gerke TA; Hinohara K; Chadalavada K; Jeong SH; Armenia J; Du SY; Mazzu YZ; Taniguchi K; Ibuki N; Meyer CA; Nanjangud GJ; Inamoto T; Lee GM; Mucci LA; Azuma H; Sweeney CJ; Kantoff PW
J Clin Invest; 2018 Jul; 128(7):2979-2995. PubMed ID: 29863497
[TBL] [Abstract] [Full Text] [Related]
17. Validation of a 10-gene molecular signature for predicting biochemical recurrence and clinical metastasis in localized prostate cancer.
Abou-Ouf H; Alshalalfa M; Takhar M; Erho N; Donnelly B; Davicioni E; Karnes RJ; Bismar TA
J Cancer Res Clin Oncol; 2018 May; 144(5):883-891. PubMed ID: 29511883
[TBL] [Abstract] [Full Text] [Related]
18. Global analysis of H3K27me3 as an epigenetic marker in prostate cancer progression.
Ngollo M; Lebert A; Daures M; Judes G; Rifai K; Dubois L; Kemeny JL; Penault-Llorca F; Bignon YJ; Guy L; Bernard-Gallon D
BMC Cancer; 2017 Apr; 17(1):261. PubMed ID: 28403887
[TBL] [Abstract] [Full Text] [Related]
19. Patient-Level DNA Damage and Repair Pathway Profiles and prognosis After prostatectomy for High-Risk prostate cancer.
Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
[TBL] [Abstract] [Full Text] [Related]
20. The Landscape of Prognostic Outlier Genes in High-Risk prostate cancer.
Zhao SG; Evans JR; Kothari V; Sun G; Larm A; Mondine V; Schaeffer EM; Ross AE; Klein EA; Den RB; Dicker AP; Karnes RJ; Erho N; Nguyen PL; Davicioni E; Feng FY
Clin Cancer Res; 2016 Apr; 22(7):1777-86. PubMed ID: 26631616
[TBL] [Abstract] [Full Text] [Related]
[Next]
